X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (170) 170
Publication (22) 22
Patent (8) 8
Book / eBook (6) 6
Book Chapter (3) 3
Book Review (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (63) 63
oncology (58) 58
index medicus (44) 44
male (42) 42
middle aged (39) 39
lung neoplasms - drug therapy (38) 38
female (35) 35
aged (32) 32
carcinoma, non-small-cell lung - drug therapy (32) 32
adult (29) 29
chemotherapy (29) 29
lung neoplasms - pathology (25) 25
respiratory system (25) 25
cancer (23) 23
lung cancer (22) 22
carcinoma, non-small-cell lung - pathology (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
treatment outcome (15) 15
docetaxel (14) 14
neoplasm staging (14) 14
carcinoma, non-small-cell lung - mortality (13) 13
lung cancer, non-small cell (13) 13
lung neoplasms - mortality (13) 13
nsclc (13) 13
trial (13) 13
antineoplastic agents - therapeutic use (12) 12
survival (12) 12
aged, 80 and over (11) 11
protein kinase inhibitors - therapeutic use (11) 11
cell lung-cancer (10) 10
disease-free survival (10) 10
life sciences (10) 10
open-label (10) 10
prognosis (10) 10
non-small cell lung cancer (9) 9
non-small-cell lung cancer (9) 9
adenocarcinoma - drug therapy (8) 8
analysis (8) 8
angiogenesis (8) 8
blasting (8) 8
devices for fastening or securing constructional elements ormachine parts together, e.g. nails, bolts, circlips, clamps,clips, wedges, joints or jointing (8) 8
double-blind (8) 8
endothelial growth-factor (8) 8
engineering elements and units (8) 8
general measures for producing and maintaining effectivefunctioning of machines or installations (8) 8
heating (8) 8
hematology, oncology and palliative medicine (8) 8
immunotherapy (8) 8
lighting (8) 8
mechanical engineering (8) 8
paclitaxel (8) 8
pulmonary/respiratory (8) 8
therapy (8) 8
thermal insulation in general (8) 8
weapons (8) 8
adenocarcinoma - pathology (7) 7
antineoplastic agents (7) 7
carboplatin (7) 7
deoxycytidine - analogs & derivatives (7) 7
disease progression (7) 7
erlotinib (7) 7
gemcitabine (7) 7
kaplan-meier estimate (7) 7
mutation (7) 7
prospective studies (7) 7
quinazolines - administration & dosage (7) 7
radiotherapy (7) 7
ramucirumab (7) 7
survival analysis (7) 7
survival rate (7) 7
tyrosine kinase inhibitors (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
bevacizumab (6) 6
carcinoma, squamous cell - drug therapy (6) 6
carcinoma, squamous cell - pathology (6) 6
care and treatment (6) 6
cisplatin (6) 6
cisplatin - administration & dosage (6) 6
clinical-trials (6) 6
erlotinib hydrochloride (6) 6
follow-up studies (6) 6
lung neoplasms - metabolism (6) 6
lung neoplasms - therapy (6) 6
medical prognosis (6) 6
patients (6) 6
phase-iii trial (6) 6
research (6) 6
resistance (6) 6
retrospective studies (6) 6
supportive care (6) 6
young adult (6) 6
1st-line chemotherapy (5) 5
antineoplastic agents - adverse effects (5) 5
cancer therapies (5) 5
carcinoma of unknown primary site (5) 5
carcinoma, non-small-cell lung - metabolism (5) 5
clinical practice guidelines (5) 5
clinical-practice guidelines (5) 5
crizotinib (5) 5
double-blind method (5) 5
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (4) 4
UTL at Downsview - May be requested (3) 3
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Stacks (1) 1
Robarts - Reference (1) 1
Royal Ontario Museum - Stacks (1) 1
St. Michael's College (John M. Kelly) - Reference (1) 1
Trinity College (John W Graham) - Reference (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Scarborough - Stacks (1) 1
Victoria University E.J. Pratt - Reference (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Translational Lung Cancer Research, ISSN 2218-6751, 2014, Volume 3, Issue 6, pp. 392 - 394
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9944, pp. 665 - 673
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2014, Volume 14, Issue 1, p. 953
Journal Article
International Journal of Environmental Research and Public Health, ISSN 1661-7827, 01/2018, Volume 15, Issue 1, p. 65
Journal Article
European Oncology and Haematology, ISSN 2045-5275, 06/2016, Volume 12, Issue 1, pp. 15 - 16
Journal Article
Future Oncology, ISSN 1479-6694, 02/2017, Volume 13, Issue 4, pp. 321 - 335
Alectinib is a highly selective second-generation ALK inhibitor that is active against most crizotinib ALK resistance mutations, with a good penetration in CNS... 
ALK | crizotinib | NSCLC | resistance mechanisms | alectinib | SAFETY | INHIBITOR ALECTINIB | ACQUIRED-RESISTANCE | PHASE I/II | ANAPLASTIC LYMPHOMA KINASE | POTENT ANTITUMOR-ACTIVITY | ONCOLOGY | PROGRESSION-FREE | PATIENTS PTS | NSCLC PATIENTS
Journal Article
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 13, pp. 21903 - 21917
Journal Article
Presse Medicale, ISSN 0755-4982, 2011, Volume 40, Issue 4, pp. 404 - 414
Standard treatment of advanced non-small cell lung cancer is based on several lines of therapy separated by treatment-free intervals in which each new line is... 
Journal Article